Compare CASH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | NUVB |
|---|---|---|
| Founded | 1954 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1996 | N/A |
| Metric | CASH | NUVB |
|---|---|---|
| Price | $82.52 | $5.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $107.50 | $11.38 |
| AVG Volume (30 Days) | 181.3K | ★ 4.3M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ 18.88 | N/A |
| EPS | ★ 4.89 | N/A |
| Revenue | ★ $839,894,000.00 | N/A |
| Revenue This Year | $7.56 | $203.82 |
| Revenue Next Year | $6.02 | $58.18 |
| P/E Ratio | $16.78 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $65.93 | $1.87 |
| 52 Week High | $101.26 | $9.75 |
| Indicator | CASH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 69.08 |
| Support Level | $81.14 | $4.13 |
| Resistance Level | $84.62 | $6.06 |
| Average True Range (ATR) | 2.28 | 0.38 |
| MACD | 0.44 | 0.10 |
| Stochastic Oscillator | 59.40 | 96.14 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.